Home›Clinical trials›Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonis

A study listed on ClinicalTrials.gov.

Recruiting now. Registry record last updated August 4, 2026.

Who can join
Adults 18+.
What you take
Check ClinicalTrials.gov for this trial's study groups and what each group receives.
How long it lasts
The study runs about 14 months.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Not ApplicableSponsor The University of Texas Health Science Center, HoustonDrug investigational drugClass OtherSites 1 USEnrollment target 136

What this study is for

Primary condition: Pulmonary Aspiration.

Full scientific study title: Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonis.

Who can join

Age18 and upSexAny

Adults 18+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists
  • Undergoing upper endoscopy only - no colonoscopy due to prep

Key exclusion criteria

  • Previous gastric resection or bypass
  • Gastric band in situ
  • Previous fundoplication
  • Large hiatal hernia
  • Pregnant patients

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Texas1 site
  • The University of Texas Health Science Center at Houston
    Houston, Texas
    Sudipta Sen, MD, FASA(713) 500-6202Sudipta.Sen@uth.tmc.edu

Timeline

Started enrolling: October 30, 2025. Expected completion: December 31, 2026. Last updated on ClinicalTrials.gov: August 4, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.